摘要目的探讨莫西沙星治疗慢性阻塞性肺疾病急性加重期的治疗效果以及安全性，为临床治疗提供理论依据。方法选取我院呼吸内科病房2016年11月至2017年3月收治的60例慢性阻塞性肺疾病急性加重期的患者作为本次研究对象，将其使用随机数字法分为两组：试验组和对照组各30例。其中试验组给予盐酸莫西沙星静点治疗，对照组给予注射用头孢哌酮钠他唑巴坦钠静点治疗。观察试验组和对照组两组患者疗效的病原菌清除率、临床症状的消失时间（包括：肺部湿啰音消失时间、体温恢复正常范围时间、咳嗽症状消失时间），病原菌清除率对比，炎症指标对比及营养状况对比，不良反应发生率。结果试验组治疗的总有效率为93.33%，明显高于本次对照组76.67%（P＜0.05）。试验组患者肺部湿啰音的消失时间为（6.1±0.3）d，体温恢复正常范围时间为（3.2±0.6）d，咳嗽症状消失时间为（5.6±1.5）d，白细胞计数恢复时间为（7.9±0.9）d，而对照组患者肺部湿啰音的消失时间为（7.8±1.2）d，体温恢复正常范围时间为（4.8±0.9）d，咳嗽症状消失时间为（7.3±2.1）d，白细胞计数恢复时间为（9.1±0.8）d，两组比较差异显著（P＜0.05）；试验组病原菌清除率为90.48%，明显高于对照组73.91%（P＜0.05）；试验组的不良反应率为6.67%，也明显低于本次研究的对照组23.33%（P＜0.05）。结论莫西沙星对治疗慢性阻塞性肺病急性加重的临床治疗效果显著，副作用少，安全性高，对各个脏器的损害小。图1幅；表7个；参75篇。关键词：莫西沙星；慢性阻塞性肺疾病；疗效；安全性AbstractObjectivesToexploretheefficacyandsafetyofmoxifloxacinonacuteexacerbationchronicobstructivepulmonarydisease,toprovidetheoreticalbasisforclinicaltreatment.Methods60casesofpatientswithchronicobstructivepulmonarydiseaseassociatedwithinfectiouspneumoniatreatedinourhospitalofdepartmentofrespirationwardfromNovember2016toMarch2017wereselectedastheresearchobject,whowererandomlydividedintoobservationgroupandcontrolgroupaccordingtotherandomdigitaltablemethod,with30casesineachgroup.Theobservationgroupweregivenmoxifloxacintreatment,andthecontrolgroupweregivencefoperazonesodiumandtazobactaminjectiontreatment.Theefficacy,pathogenicbacteriaclearace,thetimeofsymptomsdisappearedandadversereactionsofpatientsinthetwogroupswereobserved.ResultsThetotaleffectiverateintheobservationgroupwas93.33%,whichwassignificantlyhigherthanthatof76.67%inthecontrolgroup(P<0.05).Thewetralesdisappearedtimeintheobservationgroupwas(6.1±0.3)d,withtemperaturerecoverytimefor(3.2±0.6)d,coughdisappearedtimefor(5.6±1.5)d,whitebloodcellrecoverytimefor(7.9±0.9)d,whichweresignificantlylowerthan(7.8±1.2)dofwetralesdisappearedtime,(4.8±0.9)doftemperaturerecoverytime,(7.3±2.1)dofcoughdisappearedtime,(9.1±0.8)dofwhitebloodcellrecoverytimeinthecontrolgroup,andthedifferencesbetweenthetwogroupswerestatisticallysignificant(P<0.05).Theremovalrateofpathogenicbacteriaintheobservationgroupwas90.48%,whichwassignificantlyhigherthanthatof73.91%inthecontrolgroup(P<0.05).Theadversereactionrateoftheobservationgroupwas6.67%,whichwasalsosignificantlylowerthanthatof23.33%inthecontrolgroup(P<0.05).Conclusionsmoxifloxacinonacuteexacerbationchronicobstructivepulmonarydiseasehassignificanteffect,withlowadversereactionsandhighsafety.Figure1;Table4;Reference75Keywords:moxifloxacin,chronicobstructivepulmonarydisease,efficacy,safety目次引言................................................................................................................1第1章实验研究............................................................................................31.1研究目标及内容...................................................
